Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2016 · 10-Q
Revenue$1.17M$1.17M−33.0% vs Q2 2015 Net Income$24.55M$24.55MN/M vs Q2 2015 EPS Diluted$0.26$0.26N/M vs Q2 2015 Gross Profit$1,171,000−33.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$10,246,000N/M Margins · derivedGross margin100.0%±0.0 pt vs Q2 2015
Operating margin-1230.0%−458.3 pt vs Q2 2015
Net margin2096.4%+2650.5 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 9, 2016 · 40 d after period end